Fennec Pharmaceuticals Inc. (TSE:FRX) Director Chris Anigeron Rallis Sells 1,186 Shares

Fennec Pharmaceuticals Inc. (TSE:FRXGet Free Report) Director Chris Anigeron Rallis sold 1,186 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of C$9.68, for a total value of C$11,485.70.

Fennec Pharmaceuticals Price Performance

Shares of FRX stock opened at C$9.80 on Friday. The stock’s 50-day moving average is C$8.91 and its 200 day moving average is C$7.72. Fennec Pharmaceuticals Inc. has a 1-year low of C$5.65 and a 1-year high of C$15.20. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17. The company has a market cap of C$188.99 million, a P/E ratio of -166.01 and a beta of 0.25.

Analyst Upgrades and Downgrades

Separately, Stephens upgraded Fennec Pharmaceuticals to a “strong-buy” rating in a report on Monday, November 18th.

View Our Latest Stock Report on Fennec Pharmaceuticals

About Fennec Pharmaceuticals

(Get Free Report)

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.

Featured Stories

Insider Buying and Selling by Quarter for Fennec Pharmaceuticals (TSE:FRX)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.